National Vaccine and Serum Institute, Beijing, China.
J Med Virol. 2017 Dec;89(12):2075-2083. doi: 10.1002/jmv.24909. Epub 2017 Aug 29.
With the promotion of inactivated poliomyelitis vaccine (IPV) and live attenuated oral poliomyelitis vaccine (OPV), the global reported cases of poliomyelitis have reduced sharply from 0.35 million in 1988 to 74 in 2015. The Polio Eradication & Endgame Strategic Plan published by WHO in 2013 included the strategy of implementation of poliovirus safe handling and containment measures to minimize the risks of facility-associated reintroduction of virus into the polio-free community to prevent the re-import of poliovirus. Toward this strategy, we produced replication-incompetent pseudovirus of poliovirus type 1, 2, 3 attenuated strains by constructing poliovirus capsid expression vectors and poliovirus replicon then transfecting HEK293T cells and developed a pseudovirus-based neutralization assay (pNA) to determine neutralizing antibody titer which is more secure, time-saving and reliable than conventional neutralization assay (cNA). By using anti-poliovirus rat serum, we demonstrated excellent correlation between neutralizing antibody titers measured by cNA and pNA. It was concluded that pNA can be a potential alternative to replace cNA as a safe and time-saving system for titer determination after live poliovirus's safekeeping.
随着灭活脊髓灰质炎疫苗(IPV)和口服脊髓灰质炎减毒活疫苗(OPV)的推广,全球脊髓灰质炎报告病例从 1988 年的 350 万例急剧下降到 2015 年的 74 例。世界卫生组织(WHO)在 2013 年发布的《消灭脊髓灰质炎和终结脊灰策略计划》包括实施脊灰病毒安全处理和遏制措施的策略,以最大程度地降低设施相关病毒重新引入无脊髓灰质炎社区的风险,防止脊灰病毒再次输入。为此,我们构建了脊髓灰质炎病毒衣壳表达载体和脊髓灰质炎病毒复制子,转染 HEK293T 细胞,产生了 1 型、2 型、3 型减毒脊髓灰质炎病毒的复制缺陷型假病毒,开发了基于假病毒的中和测定法(pNA)来确定中和抗体滴度,与传统中和测定法(cNA)相比,pNA 更安全、省时、可靠。使用抗脊髓灰质炎病毒大鼠血清,我们证明了 cNA 和 pNA 测量的中和抗体滴度之间具有极好的相关性。研究结论表明,pNA 可以替代 cNA,作为在保存活脊髓灰质炎病毒后安全、省时的滴度测定系统。